Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected Revenues
Rhea-AI Summary
Tenon Medical (NASDAQ:TNON) said it will report fourth quarter and full year 2025 results after market close on March 19, 2026 and host a conference call the same day at 4:30 p.m. ET. The company provided revenue ranges: Q4 2025 $1.45–$1.48M (~90% YoY) and FY2025 $3.91–$3.94M (~20% YoY). Dial‑in, international numbers, webcast details, and replay access through April 2, 2026 were provided, with telephone replay access code 13758268.
Positive
- Q4 2025 revenue range of $1.45–$1.48M, ~90% year‑over‑year growth
- Full‑year 2025 revenue range of $3.91–$3.94M, ~20% year‑over‑year growth
Negative
- Full‑year revenue remains under $4.0M for 2025, indicating a small absolute revenue base
News Market Reaction – TNON
On the day this news was published, TNON declined 2.26%, reflecting a moderate negative market reaction. Argus tracked a peak move of +31.9% during that session. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $175K from the company's valuation, bringing the market cap to $8M at that time. Trading volume was exceptionally heavy at 51.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TNON is down 10.14% while peers show mixed moves: DHAI up 400%, RSLS up 29.8%, XAIR down 5.22%, and PAVM flagged in momentum down 5.26%. With gains and losses across peers and no shared news, TNON’s move appears stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | Prelim 2025 revenues | Positive | -1.6% | Preliminary Q4 and full-year 2025 revenues with strong YoY growth update. |
| Dec 04 | Product launch data | Positive | +0.0% | Initial cases and supporting data for new SImmetry+ SI Joint Fusion System. |
| Nov 14 | PIPE financing close | Neutral | +0.0% | Closing of $2.85M at-the-market PIPE with shares and warrants issued. |
| Nov 13 | Q3 2025 earnings | Neutral | -8.5% | Q3 2025 financials with higher revenue, improved margin, and net loss. |
| Nov 11 | PIPE pricing | Neutral | +0.0% | Pricing details for PIPE offering with shares and warrants to raise funds. |
Recent fundamental and financing news has often been met with flat to negative reactions, including revenue growth updates and earnings, suggesting a pattern of weak price response to operational progress.
Over the past few months, Tenon has reported substantial revenue growth, with Q3 2025 revenue of $1.2M (up 32% YoY) and preliminary Q4 2025 revenue of $1.45–$1.48M and full-year $3.91–$3.94M. The company expanded its SI fusion portfolio through the SiVantage acquisition and launched the SImmetry+ system. It also completed a $2.85M PIPE financing. Today’s earnings-date announcement largely reiterates those preliminary revenue ranges ahead of the detailed March 19, 2026 report.
Market Pulse Summary
This announcement sets expectations ahead of the March 19, 2026 earnings call, reaffirming Q4 2025 revenue guidance of $1.45–$1.48M and full-year revenue of $3.91–$3.94M. These figures follow earlier disclosures of strong year-over-year growth and product portfolio expansion. Investors may compare the final audited results to these ranges and review recent financing activity and regulatory filings to assess balance-sheet flexibility and the company’s ability to sustain growth in its sacro-pelvic treatment niche.
Key Terms
sacro-pelvic disorders medical
AI-generated analysis. Not financial advice.
Fourth Quarter 2025 Revenue of
Full Year 2025 Revenue of
LOS GATOS, CA / ACCESS Newswire / February 5, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.
Date: | Thursday, March 19, 2026 |
Time: | 4:30 p.m. Eastern time |
Dial-in: | 1-877-407-0792 |
International Dial-in: | 1-201-689-8263 |
Webcast: |
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
An audio playback of the call will be available through April 2, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13758268.
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Tenon Medical (TNON) release its Q4 and full year 2025 earnings?
What revenue did Tenon Medical (TNON) report for Q4 2025 and full year 2025?
How can investors join the Tenon Medical (TNON) earnings call on March 19, 2026?
Will Tenon Medical (TNON) provide a replay of the March 19, 2026 earnings call and how long is it available?
